Olmesartán/Amlodipino/Hidroclorotiazida Cinfa (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil/amlodipine/hydrochlorothiazide is used to manage blood pressure through several complementary mechanisms.

• Hypertension: helps achieve target blood pressure levels in adults.
• High‑risk cardiovascular patients: reduces the risk of stroke and heart attack when combined with lifestyle changes.
• Edema associated with hypertension: aids fluid reduction when added to a diuretic regimen.

• The combination product blocks angiotensin II receptors (olmesartan), relaxes vascular smooth muscle by calcium‑channel inhibition (amlodipine), and promotes sodium‑water excretion through inhibition of renal tubular reabsorption (hydrochlorothiazide). Together these actions lower systemic vascular resistance and blood volume, resulting in reduced arterial pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after the first doses.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Cough: dry, non‑productive.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips, tongue, or throat.
• Severe hypotension: symptomatic low blood pressure.
• Electrolyte disturbances: significant changes in potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: elevated liver enzymes.
• Blood dyscrasias: rare blood cell abnormalities.

When prescribing this combination, clinicians should consider patient‑specific factors and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR before initiation.
• Electrolytes: monitor serum potassium and sodium regularly.
• Hepatic status: evaluate liver function tests in patients with known disease.
• Pregnancy: avoid use during pregnancy due to fetal risk.
• Elderly patients: start at lower doses and titrate cautiously.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/amlodipine/hydrochlorothiazide may interact with several medicines; careful review is recommended.

Major Interactions (Avoid)

• Potassium‑rich supplements: risk of hyper‑kalemia.
• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine concentrations.
• Antidiabetic drugs: potential enhancement of hypoglycaemic effect.
• Other antihypertensives: additive blood‑pressure lowering leading to hypotension.